* CrCL estimated using the Cockcroft-Gault formula.
^# To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be 
contributing to the infectious process.
† To be used in combination with an antibacterial agent active against Gram-positive pathogens when 
these are known or suspected to be contributing to the infectious process.
^§ The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy.
** There is very limited experience with the use of Zavicefta for more than 14 days.

* CrCL estimated using the Cockcroft-Gault formula.
^# Dose recommendations are based on pharmacokinetic modelling (see section 5.2 of SmPC).
^† Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2 of SmPC). Dosing of 
Zavicefta on haemodialysis days should occur after completion of haemodialysis.
^§ Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are 
based on the ceftazidime component only (see section 6.6 of SmPC)